Tuesday, 21 February 2017

08.15 – 08.30  Welcome and Introduction, Ian Pavord, Alvar Agusti

**Session I: Precision medicine in airway diseases: what and how**
Chair: Peter Sterk, Netherlands

08.30 – 09.00  A label-free approach to airways disease: phenotypes, endotypes and treatable traits – Alvar Agusti, Spain

09.00 – 09.30  What are the key questions in diagnosis and management? – Elisabeth Bel, Netherlands

09.30 – 10.00  An example: Eosinophilic airway inflammation as a treatable trait – Mona Bafadhel, United Kingdom

10.00 – 10.30  General discussion

10.30 – 11.00  **Coffee break**

11.00 – 11.30  Initial trials of precision medicine approaches in airway disease – Vanessa McDonald, Australia

11.30 – 12.30  **Oral Presentation Session**
  
  **OP1** - Severe exacerbations of COPD are associated with progressive myocardial damage – Gunnar Einvik, Norway
  
  **OP2** - Beta2-receptor Genotypes and Risk of Exacerbations in Chronic Obstructive Pulmonary Disease - Truls S. Ingebrigtsen, Denmark
  
  **OP3** - Clinical effectiveness of procalcitonin based protocols to guide the administration of antibiotics in patients presenting with COPD exacerbations: Systematic review and meta-analysis - Alexander G. Mathioudakis, United Kingdom
  
  **OP4** - Connexin 37 and Connexin 43 genotypes in correlation to cytokines in induced sputum and blood in cystic fibrosis (CF) - Sabina Schmitt-Grohé, Germany

12.30 – 13.00  General discussion

13.00 – 13.45  **Lunch break**
13.45 - 14:30 Poster Session

**Session II: Breakout Paralell Session**  
Chair: Peter Gibson, Australia

14.30 – 15.15 Three Break Out Sessions to be chosen by participants  
*Three groups to discuss other candidate treatable traits. Groups should consider recognisability, treatability, importance and the likely impact of intervention against that trait and summarise their findings on a table.*

Group 1 – Pulmonary treatable traits – Peter Sterk, Netherlands  
Group 2 – Extra-pulmonary treatable traits – Elisabeth Bel, Netherlands  
Group 3 – Environmental and other treatable traits – Renaud Louis, Belgium

15.15 – 16.00 Each group to present findings (15 minutes per group)

16.00 – 16.30 Coffee break

**Session III: How to implement this approach in clinical practice**  
Chair: Elisabeth Bel, Netherlands

16.30 – 17.00 In secondary care – Richard Beasley, New Zealand  
17.00 – 17.30 In primary care – Mike Thomas, United Kingdom

17.30 – 18.00 General discussion

---

**Wednesday, 22 February 2017**

**Session IV: How to move towards precision medicine of airway diseases**  
Chair: Alvar Agusti; Ian Pavord

09.00 – 10.30 Break out session  
*Two groups to reassemble to design candidate trials*

Group 1 – Chair: Richard Beasley, New Zealand

Group 2 – Chair: Peter Gibson, Australia

10.30 – 11.00 Coffee break

11.00 – 12.20 Each groups to present main findings

12.00 – 12.30 Summary and action points – Ian Pavord, Alvar Agusti

12.30 Lunch